Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antimalarial medication |
| gptkbp:activeIngredient |
gptkb:tafenoquine
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:TGA |
| gptkbp:ATCCode |
P01BA15
|
| gptkbp:brand |
Kozenis
|
| gptkbp:CASNumber |
106635-80-7
|
| gptkbp:chemicalFormula |
C24H28F3N3O3
|
| gptkbp:contraindication |
gptkb:G6PD_deficiency
|
| gptkbp:developer |
gptkb:Medicines_for_Malaria_Venture
GlaxoSmithKline |
| gptkbp:eliminationHalfLife |
~15 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
tafenoquine (Kozenis)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
8-aminoquinoline derivative
disrupts Plasmodium mitochondrial function |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:relatedTo |
gptkb:primaquine
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting dizziness headache |
| gptkbp:usedFor |
malaria
Plasmodium vivax malaria |
| gptkbp:bfsParent |
gptkb:Medicines_for_Malaria_Venture
|
| gptkbp:bfsLayer |
7
|